This article reviews the most important biotech news this week, highlighting the breakthrough approval of Bayer’s non-hormonal menopause drug Lynkuet and the major clinical failure faced by Alector in frontotemporal …

Why KVÅ Procedure Reimbursement Matters in Sweden KVÅ procedure reimbursement is one of the most powerful—but often misunderstood—mechanisms in the Swedish healthcare system. What appears to be a simple six-character …

France has entered a new, more disciplined era in the governance of diagnostic innovation—an era in which public funding is tied directly to evidence, real-world performance, and measurable system-level value, …

How HRGs, tariffs, OPCS coding and clinical data science quietly determine how UK hospitals are funded and why this machinery shapes every diagnosis, procedure and financial decision across the NHS. …

Executive Summary: Conditional Reimbursement and Evidence-Linked Market Access Across Europe Europe’s healthcare systems are entering a new phase where biotech, pharmaceutical, MedTech, and digital innovations are funded not simply for …

How Germany’s Reimbursement System Evaluates Evidence and Cost Why the G-BA Matters In Germany, reimbursement decisions begin and end with the Gemeinsamer Bundesausschuss (G-BA) — the Federal Joint Committee responsible …